Pension fund criticizes Genmab salary packages
The statutory pension fund ATP, which holds a portion of Genmab's shares, is particularly critical of the variable part of Genmab's salary packages for the executive team and board of directors. However the proposed changes to the salaries were accepted without further issue.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN
The new changes in Genmab's salary policy, which were passed during the company's annual general meeting on Tuesday afternoon, were met with a few protests.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Analyst: Genmab share price may double
For subscribers
Genmab drug becomes more accessible in the US
For subscribers
